Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8F0G

Structure of SARS-CoV-2 Omicron BA.1 spike in complex with antibody Fab 1C3

Summary for 8F0G
Entry DOI10.2210/pdb8f0g/pdb
EMDB information28756
DescriptorAntibody 1C3 Fab Heavy Chain, Antibody 1C3 Fab Light Chain, Spike glycoprotein, ... (5 entities in total)
Functional Keywordsviral protein, glycoprotein, immune system, antibody, sars-cov-2, covid, viral protein-immune system complex, coronavirus, viral protein/immune system
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains5
Total formula weight433201.02
Authors
Yu, X.,Zyla, D.,Hastie, K.M.,Saphire, E.O. (deposition date: 2022-11-02, release date: 2023-05-03, Last modification date: 2024-11-06)
Primary citationHastie, K.M.,Yu, X.,Ana-Sosa-Batiz, F.,Zyla, D.S.,Harkins, S.S.,Hariharan, C.,Wasserman, H.,Zandonatti, M.A.,Miller, R.,Maule, E.,Kim, K.,Valentine, K.M.,Shresta, S.,Saphire, E.O.
Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence.
Cell Rep, 42:112421-112421, 2023
Cited by
PubMed Abstract: Therapeutic antibodies are an important tool in the arsenal against coronavirus infection. However, most antibodies developed early in the pandemic have lost most or all efficacy against newly emergent strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly those of the Omicron lineage. Here, we report the identification of a panel of vaccinee-derived antibodies that have broad-spectrum neutralization activity. Structural and biochemical characterization of the three broadest-spectrum antibodies reveal complementary footprints and differing requirements for avidity to overcome variant-associated mutations in their binding footprints. In the K18 mouse model of infection, these three antibodies exhibit protective efficacy against BA.1 and BA.2 infection. This study highlights the resilience and vulnerabilities of SARS-CoV-2 antibodies and provides road maps for further development of broad-spectrum therapeutics.
PubMed: 37083327
DOI: 10.1016/j.celrep.2023.112421
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.35 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon